Tony S. Mok

Sar, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 61 publications

Global advances and future directions in lung cancer care: expert consensus and strategic priorities.

Global advances and future directions in lung cancer care: expert consensus and strategic priorities.

Journal: ESMO open

Published: November 15, 2025

Alectinib versus crizotinib in previously untreated ALK-positive advanced non-small cell lung cancer: final overall survival analysis of the phase III ALEX study.

Alectinib versus crizotinib in previously untreated ALK-positive advanced non-small cell lung cancer: final overall survival analysis of the phase III ALEX study.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: August 19, 2025

Durvalumab with or without tremelimumab in combination with chemotherapy in first-line metastatic non-small-cell lung cancer: outcomes by tumor mutational burden in POSEIDON.

Durvalumab with or without tremelimumab in combination with chemotherapy in first-line metastatic non-small-cell lung cancer: outcomes by tumor mutational burden in POSEIDON.

Journal: ESMO open

Published: December 03, 2024

Concomitant Usage of H1-Antihistamines and Immune Checkpoint Inhibitors on Cancer Patient Survival.

Concomitant Usage of H1-Antihistamines and Immune Checkpoint Inhibitors on Cancer Patient Survival.

Journal: Cancer medicine

Published: September 18, 2024

Consensus on the lung cancer management after third-generation EGFR-TKI resistance.

Consensus on the lung cancer management after third-generation EGFR-TKI resistance.

Journal: The Lancet regional health. Western Pacific

Published: August 07, 2024

Lung cancer research and treatment: global perspectives and strategic calls to action.

Lung cancer research and treatment: global perspectives and strategic calls to action.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: July 09, 2024

A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON Study.

A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON Study.

Journal: Clinical lung cancer

Published: October 18, 2023

SMARCA4 deficiency and mutations are frequent in large cell lung carcinoma and are prognostically significant.

SMARCA4 deficiency and mutations are frequent in large cell lung carcinoma and are prognostically significant.

Journal: Pathology

Published: June 27, 2023

Pathologist-initiated reflex testing for biomarkers in non-small-cell lung cancer: expert consensus on the rationale and considerations for implementation.

Pathologist-initiated reflex testing for biomarkers in non-small-cell lung cancer: expert consensus on the rationale and considerations for implementation.

Journal: ESMO open

Published: February 14, 2023

Baveno VII Criteria Is an Accurate Risk Stratification Tool to Predict High-Risk Varices Requiring Intervention and Hepatic Events in Patients with Advanced Hepatocellular Carcinoma.

Baveno VII Criteria Is an Accurate Risk Stratification Tool to Predict High-Risk Varices Requiring Intervention and Hepatic Events in Patients with Advanced Hepatocellular Carcinoma.

Journal: Cancers

Published: January 30, 2023

Baveno VII criteria identify varices needing treatment in patients with hepatocellular carcinoma of different Barcelona Clinic Liver Cancer stages.

Baveno VII criteria identify varices needing treatment in patients with hepatocellular carcinoma of different Barcelona Clinic Liver Cancer stages.

Journal: Journal of gastroenterology and hepatology

Published: January 03, 2023

Withdrawal of dacomitinib treatment due to absence of toxicities is not justified.

Withdrawal of dacomitinib treatment due to absence of toxicities is not justified.

Journal: Future oncology (London, England)

Published: October 17, 2022

Showing 1-12 of 61

Last Updated: 09/26/2026